602 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
Rank Status Study
1 Recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
2 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
3 Recruiting Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions: Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Neuroendocrine Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nintedanib;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
4 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
5 Recruiting Personalized PRRT of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
6 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention:
7 Recruiting 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors
Intervention: Device: 68Ga-DOTATOC PET
8 Not yet recruiting 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Conditions: Neuroendocrine;   Neuroendocrine Tumor;   Neuroendocrine Cancer;   Neuroendocrine Carcinoma;   Carcinoid;   Carcinoid Tumor;   Islet Cell Tumor;   Apudoma
Intervention: Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
9 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
10 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
11 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
Intervention:
12 Recruiting Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors;   Neuroblastoma;   Medulloblastoma
Intervention: Drug: 68Ga-DOTATOC PET/CT
13 Recruiting Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Gastro Entero Pancreatic Neuroendocrine Tumors
Interventions: Drug: 28 GBq 177Lu-DOTATATE;   Drug: 22 GBq 177Lu-DOTATATE
14 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
Intervention:
15 Unknown  An Investigation of Small Intestinal Carcinoid Carcinoma in Families
Condition: Carcinoid Carcinoma
Intervention:
16 Available 18F-FDOPA PET in Neuroendocrine Tumours
Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
17 Recruiting RegisterNET - A Registry for Neuroendocrine Tumors in the USA
Conditions: Neuroendocrine Tumor;   Carcinoid;   Neuroendocrine Carcinoma
Intervention: Device: NETest
18 Available Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Gallium-68 DOTATOC
19 Available 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Conditions: Carcinoid Cancer;   Neuroendocrine Tumors;   Medullary Thyroid Cancer;   Cancers Expressing Somatostatin Receptors
Intervention: Drug: 68Ga DOTATATE
20 Recruiting Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Recombinant anti-tumor and anti-virus protein for injection (Novaferon)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years